Post
Late-stage biotech GID BIO wins funding from Richard King Mellon Foundation...
Late-stage biotech GID BIO wins funding from Richard King Mellon Foundation to study regenerative medicine as a potential therapeutic for severe respiratory distress Study to treat hospitalized COVID-19 patients applies...